


N30 PHARMACEUTICALS

The leader in developing new s-nitrosothiol (SNO)-based drugs

N30 Pharma's drugs target s-nitrosogluthione reductase (GSNOR), an enzyme of central importance in human health and disease.

These drugs inhibit GSNOR, the most selective enzyme that breaks down s-nitrosogluthione (GSNO), a key component of the human body's pool of bioavailable nitric oxide. GSNO and SNOs are important modulators of inflammation, cell death, organ regeneration, and respiratory, vascular, and gastrointestinal function.



Dimeric Structure of GSNOR

Inhibition of GSNOR increases the levels of endogenous, bioreactive nitric oxide. Modulating GSNOR enzymatic activity is an important new therapeutic strategy for the treatment of major diseases such as asthma, Chronic Obstructive Pulmonary Disease (COPD), inflammatory bowel disease, and vascular disease.


Highlights of N30 Pharma Development:

N30 Pharma has developed a platform of chemistry, biology, advanced analytic techniques, and state-of-the-art clinical testing. This has resulted in a broad portfolio of high potency (nM) compounds within multiple chemotypes.


N30 Pharma drug candidates have demonstrated efficacy in a broad range of human disease models. These drugs are notable in their broad anti-inflammatory activity, effect on smooth muscle, duration of effect, safety profile, and varying methods of administration, including I.V., oral, and inhalation.



These drugs are protected by a patent portfolio built upon compositional claims. N30 Pharma's first drug candidate N6022, initially targeting respiratory disease, is now entering human testing.



N30 Pharma GSNOR Inhibitors Inflammation and Airspace Enlargement in Experimental COPD



N30 Pharma GSNOR Inhibitors Preserve GI Integrity Experimental Inflammatory Bowel Disease

Executive Management

Charles Scoggin, M.D.: Chief Executive Officer

Gary Rosenthal, PhD: Executive Vice President Research

Janice Troha, VP Development and Regulatory

Tom Sokolowski, CFO and VP Finance

Scientific Advisors

Joseph Loscalzo, M.D., PhD: Harvard Medical School

Augustine Choi, M.D.: Harvard Medical School

Michael Marletta, PhD: University of California, Berkeley

Jan Wasley, PhD: Simpharma

Board of Directors

Arnold Snider: Chairman

Joseph Loscalzo, M.D., PhD: Harvard Medical School

Howard Furst, M.D.: Deerfield Management

Michael Treisman: Tiger Management

Charles Scoggin, M.D.: CEO, N30 Pharma

Dr. Evan Loh, MD, FACC, FAHA

Mr. John Moore: Array BioPharma

Investors

Tiger Management

Deerfield Management

Arnold Snider

Bridger Capital

Swift Current Partners

Duke University

N30 Pharmaceuticals, LLC

3122 Sterling Circle, Suite 200

Boulder, Colorado 80301

V: 720.945.7700

F: 303.440.8399 Web:

www.n30pharma.com

